Method and kit for prognosis of OPA1 gene induced diseases, e.g. Kjers optic atrophy.

摘要

The present invention provides the use of Nuclear factor (erythroid-derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1. CAT and ACO2 in the prognosis of an OPA1 gene- or OPA1 gene product- deficit-induced disease, or related complications, e.g. optic atrophy and optic neuropathy, in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by said disease.